VEGFA and coronary artery disorder: ATO at high doses (>0.1 μM) but not low doses reduces not only VEGFA plasma levels in coronary artery disease patients but also basal and LPS-induced VEGFA synthesis in human vascular smooth muscle cells and microvascular endothelial cells [45, 46].